Back
NM_001040108.2:c.628C>T
p.Arg210Ter · MLH3
ACMG/AMP
0%
complete
Final classification
Likely Pathogenic
PVS1PM2
MLH3
c.628C>T
p.Arg210Ter
nonsense · exon 2

MLH3 is a member of the MutL-homolog family of DNA mismatch repair genes. It partners with other family members, notably MLH1, to form a complex that detects and repairs errors in DNA during replication, safeguarding genomic stability and preventing microsatellite instability, and it also helps promote meiotic crossover. Germline mutations in MLH3 are associated with hereditary nonpolyposis colorectal cancer type 7 (HNPCC7), and inactivating changes in the gene have also been found in endometrial and gastric cancers. Loss of MLH3 function increases susceptibility to tumors such as gastrointestinal cancers, indicating that it acts as a tumor suppressor.

This variant

MLH3 encodes a MutL-homolog mismatch-repair protein that partners with MLH1 to detect and repair replication errors and protect genomic stability, and this exon 2 nonsense allele truncates that protein before its C-terminal MLH1-interaction domain, in a gene whose germline loss of function is associated with hereditary nonpolyposis colorectal cancer type 7 and other tumor predisposition.

Transcript
NM_001040108.2
HGVS · transcript:coding
NM_001040108.2:c.628C>T
GRCh38
chr14:75049028 G>A
GRCh37
chr14:75515731 G>A
Likely Pathogenic: PVS1 (very strong) for the exon 2 nonsense p.(Arg210Ter) plus PM2 (supporting) for its rarity satisfy generic ACMG/AMP 2015 rules.
Classification rationale
PVS1PM2 Likely Pathogenic
MLH3 c.628C>T nonsense · exon 2

PVS1 (very strong): nonsense p.(Arg210Ter) in exon 2 of 13 with NMD predicted removes 85.6% of MLH3, including the C-terminal MLH1-interaction domain. PM2 (supporting): gnomAD grpmax FAF 4.95e-05 (v4.1) and 2.30e-05 (v2.1) with zero homozygotes and absence from gnomAD-Canada, below the 0.0001 cut-off.

PVS1 + PM2 Likely Pathogenic
LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
Gene diagram · NM_001040108.2 · variants mapped to exon structure
MLH3 NM_001040108.2
Fetching transcript structure from UCSC…
Applied criteria · 2 applied · 16 assessed
MetEvidence satisfies this criterion.
Not metEvaluated against available evidence; threshold not reached.
Not assessedApplies in principle, but no evidence was found to evaluate it.
N/ADoesn't apply to this variant type.
Applied · 2
Strength Supporting Moderate Strong Very strong
PVS1 very strong review Pathogenic
Met at full strength: nonsense p.(Arg210Ter) in exon 2 of 13 removes 85.6% of MLH3 (1453 to 210 aa) with NMD predicted, so PVS1 is very strong.
Governing framework: generic ClinGen SVI PVS1 recommendations (registry key pvs1_generic_framework, PMC6185798; Abou Tayoun et al. 2018, PMID:30192042). The rules relied on were: PVS1 applies only where LoF is a disease mechanism for the gene/disease pair; NMD is not predicted only when the premature termination codon is in the 3'-most exon or within the 3'-most 50 bp of the penultimate exon; in the NMD-escape setting strength depends on whether more than 10% of the protein is removed (strong) or less (moderate); PVS1 must not be combined with PP3 splice predictions for the same variant; exonic null variants are downgraded where the affected exon is alternatively spliced from the major transcript, is enriched with high-frequency LoF variants in the general population, or removes a region that is not critical to protein function; and full-strength PVS1 is reserved for gene-disease pairs with definitive/strong validity, LoF variants making up >=10% of reported pathogenic variants and at least three pathogenic LoF variants classified without PVS1 across more than one exon.Variant-level conformation (registry key pvs1_variant_assessment): consequence class 'nonsense', variant bucket 'nonsense', canonical_splice_consensus false, transcript NM_001040108.2, protein NP_001035197.1:p.(Arg210Ter), framework applied = generic ClinGen SVI PVS1 recommendations, default strength for an un-downgraded call = very strong.Transcript geometry from the normalized variant record: NM_001040108.2 has 13 exons with the coding sequence at c.1-4362; the terminal exon spans c.4243 to *3307; VariantValidator reports variant_exonic_positions start_exon 2 and end_exon 2 for both GRCh37 (NC_000014.8) and GRCh38 (NC_000014.9), i.e. c.628C>T sits in exon 2 of 13, several kilobases upstream of the penultimate exon-exon junction. NM_001040108.2 is annotated MANE Select and RefSeq Select (CCDS32123.1, HGNC:7128), so it is the most biologically relevant transcript.
PM2 supporting review Pathogenic
Met at Supporting: gnomAD v4.1 grpmax FAF 4.95e-05 sits below the <=0.0001 PM2 Supporting cut-off, with zero homozygotes and absence from gnomAD-Canada.
Threshold applied: PM2 Supporting at allele frequency <= 0.0001 (ClinGen SVI 2020 recommendation to apply PM2 at Supporting strength, PMID:25741868, as calibrated for this case); no MLH3 VCEP or gene-specific PM2 threshold exists to supersede it.gnomAD v4.1 (chr14-75049028-G-A, GRCh38): total AF 4.70933e-05 (AC 76 / AN 1,613,818, homozygotes 0); exome AF 4.99376e-05 (73/1,461,824); genome AF 1.97376e-05 (3/151,994); grpmax FAF 4.945e-05; popmax/ancestry maximum European (non-Finnish) 6.10167e-05 (72/1,180,004).gnomAD v2.1 (14-75515731-G-A, GRCh37, exomes only): total AF 2.79176e-05 (AC 7 / AN 250,738, homozygotes 0); grpmax FAF 2.298e-05; popmax European (non-Finnish) 5.28811e-05 (6/113,462); all ancestry groups <= 5.3e-05.
Assessed · not applied · 11 not met · 5 not assessed
Pathogenic
PS2 Not assessed: no proband or parental genotype data are available, so a confirmed de novo occurrence for c.628C>T cannot be established.
PS3 Not met: no functional assay has tested c.628C>T, and the only MLH3 assay (engineered N-terminal deletion construct) does not address this variant.
PS4 Not met: no case-control or cohort enrichment data exists for c.628C>T, so prevalence in affected individuals cannot be shown to exceed gnomAD control frequency.
PM3 Not met: no MLH3 pathogenic variant is reported in trans with c.628C>T in any ClinVar submission or paper, so the recessive in-trans requirement is unmet.
PM6 Not assessed: with no proband and no parental phenotype or testing information, an assumed de novo occurrence cannot even be inferred.
PP1 Not assessed: no pedigree, affected relatives or genotype data exist, so no informative meioses can be counted for co-segregation.
PP4 Not assessed: no proband phenotype or family history is recorded, and MLH3 is absent from the Lynch-syndrome gene lists (MLH1, MSH2, MSH6, PMS2) cited in the guidelines.
PP5 Not met: ClinVar variation 860534 has zero expert-panel submissions; its three submissions are ordinary single-laboratory assertions (2 Uncertain significance, 1 Pathogenic).
Benign
BA1 Not met: highest population frequency is 6.10e-05 (gnomAD v4.1 European non-Finnish), roughly 820-fold below the >=0.05 BA1 stand-alone threshold.
BS1 Not met: peak ancestry frequency 6.10e-05 (gnomAD v4.1 European non-Finnish) is roughly 164-fold below the >=0.01 BS1 strong threshold.
BS2 Not met: zero homozygotes in gnomAD v4.1 (1,613,818 alleles) and v2.1, and MLH3 disease is adult-onset rather than early-onset fully penetrant.
BS3 Not met: no assay reports normal function for c.628C>T; the only MLH3 functional study tested an engineered deletion construct, not this variant.
BS4 Not assessed: no pedigree or relative genotypes exist, so non-segregation of c.628C>T with disease cannot be demonstrated.
BP2 Not met: no cis/trans phasing with a pathogenic variant is documented in any ClinVar submission or paper, and gnomAD reports zero homozygotes for c.628C>T.
BP5 Not met: no case carrying c.628C>T is reported with a documented alternate molecular basis of disease.
BP6 Not met: ClinVar variation 860534 contains no expert-panel submission and no Benign or Likely benign assertion for c.628C>T.
N/A · 10 PS1 · PM1 · PM4 · PM5 · PP2 · PP3 · BP1 · BP3 · BP4 · BP7
Research & evidence
Population frequency · supports pathogenic
gnomAD v4.1 screenshot
gnomAD v4.1
gnomAD v2.1 screenshot
gnomAD v2.1
v4.1
This variant is present in gnomAD v4.1 (AF= 4.70933e-05; MAF= 0.00471%, 76/1613818 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 6.10167e-05; MAF= 0.00610%, 72/1180004 alleles, homozygotes = 0); grpmax FAF= 4.945e-05.
v2.1
This variant is present in gnomAD v2.1 (AF= 2.79176e-05; MAF= 0.00279%, 7/250738 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 5.28811e-05; MAF= 0.00529%, 6/113462 alleles, homozygotes = 0); grpmax FAF= 2.298e-05.
🇨🇦 CA
Absent from gnomAD-Canada v1.0.
Allele frequency by ancestry
three datasets · side by side
gnomAD v4.1
0.0047% · 76 / 1,613,818
0 hom · FAF 0.0049%
European (non-Finnish)
72 / 1,180,004
0.0061%
East Asian
2 / 44,892
0.0045%
Admixed American
1 / 59,972
0.0017%
African/African American
1 / 74,846
0.0013%
+ 6 not observed (Remaining individuals, European (Finnish), Amish, Middle Eastern, South Asian, Ashkenazi Jewish)
gnomAD v2.1
0.0028% · 7 / 250,738
0 hom · FAF 0.0023%
European (non-Finnish)
6 / 113,462
0.0053%
Admixed American
1 / 34,544
0.0029%
+ 6 not observed (African/African American, Ashkenazi Jewish, East Asian, European (Finnish), Remaining individuals, South Asian)
gnomAD Canada 🇨🇦
Absent · 0 / ?
0 hom
Not observed in any ancestry group.
ClinVar screenshot
ClinVar
This variant has been reported in ClinVar as Uncertain significance (2 clinical laboratories) and as Pathogenic (1 clinical laboratory). (ClinVarID = 860534)
SpliceAI screenshot
In silico
SpliceAI predicts no significant splice impact for this variant (max delta score = 0.00). BayesDel score = 0.66.
Functional / OncoKB screenshot
Functional Likely Oncogenic
OncoKB identified variant-specific curated literature and context relevant to functional review; biological-effect context: Likely Loss-of-function; curated oncogenicity label: Likely Oncogenic.
OncoKB ↗
COSMIC screenshot
COSMIC
Cancer hotspots screenshot
Cancer hotspots
Somatic evidence Not in COSMIC / hotspots
COSMIC
This variant does not lie in a statistically significant hotspot. This variant has previously been reported in somatic cancers (COSMIC; COSV53134876, n = 1 times).
Hotspots
This variant does not lie in a statistically significant hotspot.
Literature · how each cited paper was used
5papers cited
Each card is an audit: what was searched, what was found, whether it names the variant, which criteria it fed, and why. 2 further PMIDs triaged but not cited — see Sources & references.
Rule & framework references · cited for criterion definitions, not variant evidence
10615123 ↗ MLH3: a DNA mismatch repair gene associated with mammalian microsatellite instability.
24493721 ↗ American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers.
25741868 ↗ Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
33516529 ↗ Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations.
34043773 ↗ European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender.
Sources & reference links
8Sources
ClinVar
gnomAD v2.1
gnomAD v4.1
gnomAD-Canada
SpliceAI
OncoKB
COSMIC
Cancer hotspots
Triaged references · 2 PMIDs not cited in assessment
33451724 ↗ Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations, part II. CLINVAR
24929052 ↗ Endometrial cancer: a review and current management strategies: part II. CLINVAR